Extended resection of sarcomas involving the mediastinum: a 15-year experience†.

OBJECTIVES: Sarcomas involving the mediastinum are rare and aggressive tumours with a poor prognosis. We reviewed our experience to evaluate outcomes and survival for patients who undergo surgical resection. METHODS: A retrospective review of 35 patients who underwent resection of sarcomas that involved the mediastinum at a single institution over a 15-year period was conducted. RESULTS: Fifteen patients (43%) had sarcomas originating from the great vessels, 15 (43%) the heart and 5 (15%) the chest wall. The most common subtype was leiomyosarcoma (n = 10, 29%). Twenty patients (57%) underwent resection of primary tumours, 11 (31%) of metastases and 4 (11%) of recurrences. Sixteen patients (46%) had Stage IV disease. An R0 resection was achieved in 17 patients (49%). Fourteen (40%) had an R1 resection and 4 (11%) an R2. Thirty cases (85%) were performed on cardiopulmonary bypass (CPB). Twenty-three patients (65%) required resection of adjacent structures. Eight cases (23%) were performed on an urgent basis. Morbidity and mortality were 37 and 6%, respectively. Overall median survival was 33 months (range 7-171 months). Median overall survival for Stage IV disease was 5 months compared with 27 months for all others (P = 0.26). Two-, 5- and 10-year survivals for the cohort were 50, 35 and 25%, respectively. Incomplete resection was associated with poor long-term survival. Median survival was 101 months for R0, 21 months for R1 and 9 months for R2 resection. CONCLUSIONS: CPB and concomitant resection of intrathoracic structures may be required for local tumour control in sarcomas that involve the mediastinum, and should not be considered contraindications to resection as they may offer the best opportunity for prolonged survival in selected cases.

Safety and efficacy of retrograde cerebral perfusion as an adjunct for cerebral protection during surgery on the aortic arch.

OBJECTIVE: The best adjunct for cerebral protection during aortic arch reconstruction remains controversial. Retrograde cerebral perfusion (RCP) as an adjunct to profound hypothermic circulatory arrest (PHCA) extends the tolerable period of brain ischemia by flushing emboli and air from the cerebral circulation while maintaining hypothermia. We examined our experience with RCP to determine its efficacy in patients undergoing complex arch reconstruction. METHODS: We retrospectively evaluated 879 patients undergoing arch reconstruction using RCP from July 1997 to March 2013. Perioperative risk factors were analyzed as predictors of neurologic injury and mortality. Survival for the type of arch reconstruction and for the interval of PHCA was calculated. RESULTS: Of the 879 patients, 671 underwent hemiarch and 208 total arch replacement. The mean age was 65 ± 13.3 years, and 61.6% were men. The total arch patients had longer mean periods of PHCA (39 vs 21 minutes, P < .001) and RCP (37 vs 19 minutes, P < .001). However, the incidence of transient neurologic dysfunction (3.0% vs 2.4%, P < .813) and permanent neurologic dysfunction (1.3% vs 1.9%, P < .519) was similar for both techniques. Mortality was greater in the hemiarch group (4.8% vs 0.5%, P < .003). Patients requiring >40 minutes of PHCA had outcomes similar to those requiring less. The 1-, 5-, and 10-year survival was similar, regardless of the procedure performed or interval of PHCA. CONCLUSIONS: RCP is a safe and effective adjunct for cerebral protection during arch surgery. Patients requiring more extensive arch reconstruction are not at greater risk of permanent neurologic dysfunction or perioperative mortality.